The short version of visceral fat fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-16 and is reviewed periodically as new material appears.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Capitalizing on the popularity of the Apollo space missions in the early 1970s, Pillsbury marketed "Food Sticks" (also known as "Space Food Sticks") for the consumer market. Fourteen individually packaged sticks were included in a box, and came in six flavors such as peanut butter, caramel, and chocolate. Food Sticks were marketed as a "nutritionally balanced between meal snack". Examples of derivative products can be found in NASA Space Center gift shops, general sweets and novelty shops, online retailers, or at Army Surplus stores. A popular example is freeze-dried ice cream. Tang, originally marketed in 1959, saw an increase in popularity in the 1960s due to its inclusion on American human space flights.
=== Liver injury === Methimazole is commonly associated with transient, mild, asymptomatic elevations in serum aminotransferase levels, typically during the first months of treatment with a high dose. More serious liver injury can, usually with a cholestatic or mixed pattern of enzyme elevations and prolonged cholestatic hepatitis. Methimazole induced liver injury fatalities are rare and symptoms and jaundice usually clear within 2-8 weeks of stopping the drug. In most cases switching to propylthiouracil does not result in a recurrence of liver injury. To differentiate methimazole induced liver injury from liver injury related to the underlying hyperthyroidism, it is recommended to check baseline liver enzymes prior to initiation of treatment. Other known side effects include:
== Fuels and consumption == Ashing is a test to deduce the amount of ash forming material present in a petroleum product so as to decide its use in certain applications. Ash-forming materials are considered to be undesirable impurities or contaminants. In the ash analysis of petroleum products, ash content represents the incombustible component remaining after a sample of the furnace oil is completely burned. The ash content of petroleum products is generally low. It is defined as the inorganic residue that remains after combustion of the oil in air at specific high temperature. Ash typically ranges from 0.1 to 0.2% in oil. Some of the ash forming constituents occur naturally in crude oil; others are present as a result of refining or contamination during storage or distribution. Knowledge of the amount of ash-forming material present in a product can provide information as to whether or not the product is suitable application. In the ash analysis of coal and other solid fuels, the amount of sulfur retained in the ash during the ashing process is not constant, but rather is dependent upon the conditions of ashing as well as the other inorganic constituents in the ash that may form sulfates during the ashing procedure. As such, different ashing procedures may yield different ash contents.
==== Competitive assays ==== Competitive assays are generally used for smaller analytes since smaller analytes have fewer binding sites. The sample first encounters antibodies to the target analyte labelled with a visual tag (colored particles). The test line contains the target analyte fixed to the surface. When the target analyte is absent from the sample, unbound antibody will bind to these fixed analyte molecules, meaning that a visual marker will show. Conversely, when the target analyte is present in the sample, it binds to the antibodies to prevent them binding to the fixed analyte in the test line, and thus no visual marker shows. This differs from sandwich assays in that no band means the analyte is present.
IGFRs and estrogen coaction facilitates growth in different breast cancer cell lines, however amplification of IGF1R signalling can abrogate need of estrogen for transformation and growth of MCF-7 cells. IRS-1 overexpression in breast cancer cells decreased estrogen requirements. This decrease is dependent on IRS-1 levels in the cells. Estradiol enhances expression of IRS-1 and activity of ERK1/2 and PI3K/Akt pathways in MCF-7 and CHO cells transfected with mouse IRS-1 promoter. Estradiol acts directly on IRS-1 regulatory sequences and positively regulates IRS-1 mRNA production. Decreased anchorage- dependent/independent cell growth and initiation of cell death under low growth factor and estrogen conditions are observed in MCF-7 cells with down-regulated IRS-1. mir126 is underexpressed in breast cancer cells. mir126 targets IRS-1 at transcriptional level and inhibits transition from G1/G0 phase to S phase during cell cycle in HEK293 and MCF-7 cells. Transgenic mice overexpressing IRS-1 develop metastatic breast cancer. The tumors demonstrate squamous differentiation which is associated with β-catenin pathway. IRS-1 interacts with β-catenin both in vitro and in vivo. IRS-1 and its homologue IRS-2 play distinct roles in breast cancer progression and metastasis. Overexpression of either one is sufficient to cause tumorogenesis in vivo. Frequency of lung metastasis in IRS-1 deficient tumor is elevated opposing to IRS-2 deficient tumor, where it is decreased.
Sources: en.wikipedia.org
One of these first-generation IUDs was the Dalkon Shield, whose poor design caused bacterial infection and led to thousands of lawsuits. Although it was removed from the market, the Dalkon Shield had a lasting, negative impact on IUD use and reputation in the United States. The invention of the copper IUD in the 1960s introduced the capital T-shaped design used by most modern IUDs. U.S. physician Howard Tatum determined this shape would work better with the space of the uterine cavity. He predicted this would reduce rates of IUD expulsion. Further, Tatum and Chilean physician Jaime Zipper discovered that copper could be an effective spermicide and developed the first copper IUD. Improvements by Tatum led to the creation of the TCu380A (ParaGard), which is the preferred copper IUD since 1997. The hormonal IUD was also invented in the 1960s and 1970s with the goal of mitigating the increased menstrual bleeding associated with copper and inert IUDs. The first model, Progestasert, lasted for one year of use and was quickly discontinued. The Mirena hormonal IUD was released in 1976.
The transition from capitalism to socialism was signified by the introduction of the first five-year plan and the 1936 Soviet Constitution. By the late 1920s, Stalin established ideological orthodoxy in the CPSU, Soviet Union, and Communist International to establish universal Marxist–Leninist praxis. The formulation of the Soviet version of dialectical and historical materialism by Stalin and his associates, such as in Stalin's text Dialectical and Historical Materialism, became the official Soviet interpretation of Marxism, and was taken as example by Marxist–Leninists in other countries. This text became the foundation philosophy of Marxism–Leninism. In 1938, Stalin's textbook History of the Communist Party of the Soviet Union (Bolsheviks) popularised Marxism–Leninism. The internationalism of Marxism–Leninism was expressed in supporting revolutions in other countries, initially through the Communist International, then through the concepts of national democratic states and states of socialist orientation after de-Stalinisation. The establishment of other communist states after World War II resulted in Sovietisation, and these states tended to follow the Marxist–Leninist model of five-year plans and rapid industrialisation, political centralisation, and repression. During the Cold War, Marxist–Leninist countries like the Soviet Union were a major force in international relations.
There are various preparations of gonadotropins for therapeutic use, mainly as fertility medication. For example, the so-called menotropins (also called human menopausal gonadotropins) consist of LH and FSH extracted from the urine of menopausal women. There are also recombinant variants. Besides the aforementioned legitimate pharmaceutical drugs, there are fad diet or quack preparations, which are illegal in various countries.
=== Asthma === Magnesium sulfate may be used as bronchodilator after beta-agonist and anticholinergic agents have been tried, e.g. in severe exacerbations of asthma, The salt can be administered by nebulization or by intravenous injection.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.